^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KRAS peptide vaccine

i
Associations
Company:
Sidney Kimmel Comprehensive Cancer Center
Drug class:
Immunostimulant, KRAS inhibitor
Related drugs:
Associations
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
02/03/2025
Initiation :
05/28/2020
Primary completion :
08/08/2025
Completion :
08/08/2025
KRAS • CD8 • CD4
|
KRAS mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Not yet recruiting
Last update posted :
01/20/2025
Initiation :
04/01/2025
Primary completion :
12/01/2028
Completion :
12/01/2028
CD20
|
cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
09/04/2023
Initiation :
04/11/2022
Primary completion :
05/01/2026
Completion :
05/01/2026
KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1
|
KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation
|
Hiltonol (poly-ICLC) • KRAS peptide vaccine